An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Aug 12

PMID 35954477

Authors

Emily K Colvin

Amanda L Hudson

Lyndsey L Anderson

Ramyashree Prasanna Kumar

Iain S McGregor

Viive M Howell

Jonathon C Arnold

Affiliations

Soon will be listed here.

Abstract

Mesothelioma is an aggressive cancer with limited treatment options and a poor prognosis. Phytocannabinoids possess anti-tumour and palliative properties in multiple cancers, however their effects in mesothelioma are unknown. We investigated the anti-cancer effects and potential mechanisms of action for several phytocannabinoids in mesothelioma cell lines. A panel of 13 phytocannabinoids inhibited growth of human (MSTO and H2452) and rat (II-45) mesothelioma cells in vitro, and cannabidiol (CBD) and cannabigerol (CBG) were the most potent compounds. Treatment with CBD or CBG resulted in G0/G1 arrest, delayed entry into S phase and induced apoptosis. CBD and CBG also significantly reduced mesothelioma cell migration and invasion. These effects were supported by changes in the expression of genes associated with the cell cycle, proliferation, and cell movement following CBD or CBG treatment. Gene expression levels of , , and also increased with CBD or CBG treatment. However, treatment with CBD or CBG in a syngeneic orthotopic rat mesothelioma model was unable to increase survival. Our data show that cannabinoids have anti-cancer effects on mesothelioma cells in vitro and alternatives of drug delivery may be needed to enhance their effects in vivo.

Citing Articles

Genotoxicity of selected cannabinoids in human lymphoblastoid TK6 cells.

Kolar N, Bankoglu E, Stopper H Arch Toxicol. 2024; 98(10):3439-3451.

PMID: 39172143 PMC: 11402852. DOI: 10.1007/s00204-024-03826-y.

Anticancer effect of minor phytocannabinoids in preclinical models of multiple myeloma.

Aguzzi C, Zeppa L, Morelli M, Marinelli O, Giangrossi M, Amantini C Biofactors. 2024; 50(6):1208-1219.

PMID: 38760945 PMC: 11627469. DOI: 10.1002/biof.2078.

Cannabidivarin and cannabigerol induce unfolded protein response and angiogenesis dysregulation in placental trophoblast HTR-8/SVneo cells.

Alves P, Amaral C, Goncalves M, Teixeira N, Correia-da-Silva G Arch Toxicol. 2024; 98(9):2971-2984.

PMID: 38748041 PMC: 11324689. DOI: 10.1007/s00204-024-03781-8.

Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review.

Wilson G, Yang L, Su X, Ding S, Li L, Yang Y Pharmacol Rep. 2023; 75(6):1410-1444.

PMID: 37906390 DOI: 10.1007/s43440-023-00544-7.

Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy.

Voicu V, Brehar F, Toader C, Covache-Busuioc R, Corlatescu A, Bordeianu A Biomolecules. 2023; 13(9).

PMID: 37759788 PMC: 10526757. DOI: 10.3390/biom13091388.

References

McAllister S, Soroceanu L, Desprez P . The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. J Neuroimmune Pharmacol. 2015; 10(2):255-67. PMC: 4470774. DOI: 10.1007/s11481-015-9608-y. View

Echeverry N, Ziltener G, Barbone D, Weder W, Stahel R, Broaddus V . Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors. Cell Death Dis. 2015; 6:e1757. PMC: 4669703. DOI: 10.1038/cddis.2015.124. View

Melaiu O, Cristaudo A, Melissari E, Di Russo M, Bonotti A, Bruno R . A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. Mutat Res. 2011; 750(2):132-140. DOI: 10.1016/j.mrrev.2011.12.003. View

Desprez P, Murase R, Limbad C, Woo R, Adrados I, Weitenthaler K . Cannabidiol Treatment Results in a Common Gene Expression Response Across Aggressive Cancer Cells from Various Origins. Cannabis Cannabinoid Res. 2021; 6(2):148-155. PMC: 8064952. DOI: 10.1089/can.2019.0081. View

Ramer R, Bublitz K, Freimuth N, Merkord J, Rohde H, Haustein M . Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J. 2011; 26(4):1535-48. DOI: 10.1096/fj.11-198184. View

Nahler G . Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics. Pharmaceut Med. 2022; 36(2):99-129. PMC: 9021107. DOI: 10.1007/s40290-022-00420-4. View

Anderson L, Absalom N, Abelev S, Low I, Doohan P, Martin L . Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019; 60(11):2224-2234. PMC: 6900043. DOI: 10.1111/epi.16355. View

Anderson L, Low I, Banister S, McGregor I, Arnold J . Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome. J Nat Prod. 2019; 82(11):3047-3055. DOI: 10.1021/acs.jnatprod.9b00600. View

Liu T, Zhang L, Joo D, Sun S . NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017; 2. PMC: 5661633. DOI: 10.1038/sigtrans.2017.23. View

10.

Anderson L, Ametovski A, Luo J, Everett-Morgan D, McGregor I, Banister S . Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. ACS Chem Neurosci. 2021; 12(2):330-339. DOI: 10.1021/acschemneuro.0c00677. View

11.

Braile M, Marcella S, Marone G, Galdiero M, Varricchi G, Loffredo S . The Interplay between the Immune and the Endocannabinoid Systems in Cancer. Cells. 2021; 10(6). PMC: 8224348. DOI: 10.3390/cells10061282. View

12.

Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling C, Arifin S . GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene. 2018; 37(49):6368-6382. DOI: 10.1038/s41388-018-0390-1. View

13.

Roe O, Stella G . Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev. 2015; 24(135):115-31. PMC: 9487774. DOI: 10.1183/09059180.00007014. View

14.

Brims F . Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma. Cancers (Basel). 2021; 13(16). PMC: 8391310. DOI: 10.3390/cancers13164194. View

15.

Olsen N, Franklin P, Reid A, de Klerk N, Threlfall T, Shilkin K . Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust. 2011; 195(5):271-4. DOI: 10.5694/mja11.10125. View

16.

Wischhusen J, Melero I, Fridman W . Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020; 11:951. PMC: 7248355. DOI: 10.3389/fimmu.2020.00951. View

17.

Weir C, Hudson A, Peters L, Howell V . Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model. J Vis Exp. 2015; (104). PMC: 4692642. DOI: 10.3791/53019. View

18.

Lassalas P, Gay B, Lasfargeas C, James M, Tran V, Vijayendran K . Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem. 2016; 59(7):3183-203. PMC: 4833640. DOI: 10.1021/acs.jmedchem.5b01963. View

19.

Mangal N, Erridge S, Habib N, Sadanandam A, Reebye V, Sodergren M . Cannabinoids in the landscape of cancer. J Cancer Res Clin Oncol. 2021; 147(9):2507-2534. PMC: 8310855. DOI: 10.1007/s00432-021-03710-7. View

20.

Formato M, Crescente G, Scognamiglio M, Fiorentino A, Pecoraro M, Piccolella S . (‒)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research. Molecules. 2020; 25(11). PMC: 7321064. DOI: 10.3390/molecules25112638. View